Replimune Gains Favorable 10-3 FDA Advisory Vote for Melanoma Therapy
Question
Replimune Gains Favorable 10-3 FDA Advisory Vote for Melanoma Therapy
Direct answer
Increased probability of FDA approval leading to binary valuation re-rating. — bullish pressure on REPL via regulatory approval probability.
- Original publisher
- Market Ontology
- Evidence through
- 2026-07-31
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Replimune Gains Favorable 10-3 FDA Advisory Vote for Melanoma Therapy”, revision 1, evidence through 2026-07-31. https://marketontology.com/catalysts/2026-07-31/replimune-gains-favorable-10-3-fda-advisory-vote-for-melanoma-therapy-03f309
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| REPL | ▲Bull | 1–4 weeks | regulatory approval probability | 59 |
Replimune Gains Favorable 10-3 FDA Advisory Vote for Melanoma Therapy
Increased probability of FDA approval leading to binary valuation re-rating. — bullish pressure on REPL via regulatory approval probability.
FDA advisory committee voted 10-3 in favor
- SourceFDA advisory committee voted 10-3 in favor
- TransmissionIncreased probability of FDA approval leading to binary valuation re-rating.
- SummaryReplimune clears a major regulatory hurdle for its lead candidate. The 10-3 vote provides a strong tailwind heading into the August 15 deadline. RP1 is used in combination with nivolumab (Opdivo).
- REPLDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- REPL closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- REPL price vs. pre-event level
- REPL volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Replimune Announces Favorable Outcome of FDA's Advisory Committee Meeting · news · 2026-07-30
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.